- Home
- ABTC vs SKYE Comparison
ABTC vs SKYE Comparison
Compare ABTC & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABTC
- SKYE
- Stock Information
- Founded
- ABTC 2024
- SKYE 2012
- Country
- ABTC United States
- SKYE United States
- Employees
- ABTC N/A
- SKYE N/A
- Industry
- ABTC EDP Services
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- ABTC Technology
- SKYE Health Care
- Exchange
- ABTC Nasdaq
- SKYE Nasdaq
- Market Cap
- ABTC 122.5M
- SKYE 108.5M
- IPO Year
- ABTC N/A
- SKYE N/A
- Fundamental
- Price
- ABTC N/A
- SKYE $4.15
- Analyst Decision
- ABTC
- SKYE Buy
- Analyst Count
- ABTC 0
- SKYE 7
- Target Price
- ABTC N/A
- SKYE $15.50
- AVG Volume (30 Days)
- ABTC 15.8M
- SKYE 292.8K
- Earning Date
- ABTC 11-08-2025
- SKYE 11-06-2025
- Dividend Yield
- ABTC N/A
- SKYE N/A
- EPS Growth
- ABTC N/A
- SKYE N/A
- EPS
- ABTC N/A
- SKYE N/A
- Revenue
- ABTC N/A
- SKYE N/A
- Revenue This Year
- ABTC N/A
- SKYE N/A
- Revenue Next Year
- ABTC N/A
- SKYE N/A
- P/E Ratio
- ABTC N/A
- SKYE N/A
- Revenue Growth
- ABTC N/A
- SKYE N/A
- 52 Week Low
- ABTC $6.24
- SKYE $1.14
- 52 Week High
- ABTC $14.52
- SKYE $7.11
- Technical
- Relative Strength Index (RSI)
- ABTC N/A
- SKYE 65.13
- Support Level
- ABTC N/A
- SKYE $3.28
- Resistance Level
- ABTC N/A
- SKYE $3.61
- Average True Range (ATR)
- ABTC 0.00
- SKYE 0.26
- MACD
- ABTC 0.00
- SKYE 0.08
- Stochastic Oscillator
- ABTC 0.00
- SKYE 98.98
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.